Category: antibiotic

  • US study finds high rates of unneeded antibiotic prescribing

    A study has found that there is still a very high level of inappropriate antibiotic prescribing to patients in the US, particularly to older and Black patients. Sifting through data from around seven billion outpatient visits to doctor’s offices, hospital clinics and emergency departments over a seven-year period, the researchers found that almost three-quarters (74%) […]

  • UK launches its ‘Netflix-style’ payment model for antibiotics

    The UK is poised to become the first country in the world to launch a new payment model for antibiotics that could reverse decades of decline into the category. The Department of Health, NHS England and NICE have completed an evaluation of two new antibiotics – Pfizer’s Zavicefta (ceftazidime/avibactam) and Shionogi’s Fetcroja (cefiderocol) – that […]

  • Sandoz, Ares extend digital alliance on antimicrobial resistance

    Novartis’ generics unit Sandoz has moved on to the next stage of a collaboration with Ares Genetics, which is focusing on the use of artificial intelligence to track antimicrobial resistance (AMR), improve diagnoses and guide the most effective use of antibiotics. Sandoz and Ares – a subsidiary of OpGen – started working together in 2018, […]

  • Pharma-backed antibiotic fund makes first investments

    Two years after it was first proposed and a year after it officially launched, the pharma-backed AMR Action Fund has made its first investments in companies trying to tackle the pressing problem of antibiotic resistance. The Fund – set up as a public-private partnership by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) – […]

  • Venatorx plans new antibiotic filing after phase 3 readout

    Venatorx Pharma has moved a step closer to what has unfortunately become a rare event in pharma – the filing of a new antibiotic designed to tackle the increasing pressing problem of antimicrobial resistance. Armed with positive phase 3 results, Venatorx has said till file for approval its cefepime-taniborbactam combination with the FDA later this […]

  • Novartis antibiotic retreat doesn’t stop Sandoz buying GSK drugs

    Novartis exited novel antibiotics R&D three years ago, but is clearly still interested in the category – its Sandoz unit has just spent $350 million buying GlaxoSmithKline’s cephalosporin franchise.  The deal covers global rights to three brands – Zinnat (cefuroxime axetil), Zinacef (cefuroxime) and Fortum (ceftazidime) – which are sold in more than 100 markets […]